Axsome Therapeutics Inc
NASDAQ:AXSM

Watchlist Manager
Axsome Therapeutics Inc Logo
Axsome Therapeutics Inc
NASDAQ:AXSM
Watchlist
Price: 178.69 USD -2.16% Market Closed
Market Cap: 9B USD

Axsome Therapeutics Inc
Intangible Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Axsome Therapeutics Inc
Intangible Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Intangible Assets CAGR 3Y CAGR 5Y CAGR 10Y
Axsome Therapeutics Inc
NASDAQ:AXSM
Intangible Assets
$42m
CAGR 3-Years
-12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Intangible Assets
$48.7B
CAGR 3-Years
7%
CAGR 5-Years
1%
CAGR 10-Years
6%
Bristol-Myers Squibb Co
NYSE:BMY
Intangible Assets
$20.5B
CAGR 3-Years
-19%
CAGR 5-Years
-18%
CAGR 10-Years
29%
Pfizer Inc
NYSE:PFE
Intangible Assets
$51.3B
CAGR 3-Years
22%
CAGR 5-Years
11%
CAGR 10-Years
2%
Merck & Co Inc
NYSE:MRK
Intangible Assets
$15.3B
CAGR 3-Years
-11%
CAGR 5-Years
-2%
CAGR 10-Years
-4%
Eli Lilly and Co
NYSE:LLY
Intangible Assets
$6.4B
CAGR 3-Years
-3%
CAGR 5-Years
-3%
CAGR 10-Years
3%
No Stocks Found

Axsome Therapeutics Inc
Glance View

Axsome Therapeutics Inc. emerged as a dynamic player in the biopharmaceutical arena, driven by a resolute commitment to alleviate the burdensome effects of central nervous system (CNS) disorders. Founded with a vision to fill critical treatment gaps in neurologically influenced conditions, Axsome leverages innovative drug discovery and development to address medical needs that have long been underserved. The company focuses intently on conditions such as depression, migraine, narcolepsy, and Alzheimer's disease-related agitation, channeling resources into a streamlined pipeline that seeks to fast-track the development and commercialization of life-changing therapies. Operating at the intersection of cutting-edge science and patient-centric healthcare, Axsome generates revenue through the successful approval and marketing of its proprietary pharmaceutical products. The company's business model hinges on advancing its clinical candidates through rigorous trials, eventually gaining the necessary regulatory endorsements to bring them to market. By holding the intellectual property rights for these novel drugs, Axsome enjoys the advantages of exclusivity in the marketplace, which allows it to negotiate favorable pricing and reimbursement terms. This strategic approach not only positions Axsome as a potentially transformative force within the pharmaceutical industry but also underlines its commitment to producing viable, accessible treatments for those grappling with debilitating CNS disorders.

AXSM Intrinsic Value
144.81 USD
Overvaluation 19%
Intrinsic Value
Price

See Also

What is Axsome Therapeutics Inc's Intangible Assets?
Intangible Assets
42m USD

Based on the financial report for Sep 30, 2025, Axsome Therapeutics Inc's Intangible Assets amounts to 42m USD.

What is Axsome Therapeutics Inc's Intangible Assets growth rate?
Intangible Assets CAGR 3Y
-12%

Over the last year, the Intangible Assets growth was -14%. The average annual Intangible Assets growth rates for Axsome Therapeutics Inc have been -12% over the past three years .

Back to Top